Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies

·        Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.

Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases.

Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people’s way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana’s drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health.

“We’re looking forward to team up with Re-Vana to push the boundaries of what’s possible in eye health,” said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. “Together, we want to tackle the limits of today’s treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.” 

“The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,” said Michael O’Rourke, Re-Vana Chief Executive Officer. “By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.”

Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.  

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at https://www.boehringer-ingelheim.com (Global) or https://www.boehringer-ingelheim.com/uk (UK).  

About Re-Vana Therapeutics

Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen’s University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. 

Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset.  Learn more at https://www.revanatx.com/

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contacts 

 

Boehringer Ingelheim: 
Dr. Reinhard Malin

Boehringer Ingelheim Corporate Center GmbH 
Innovation Unit/Bio Comms, Corp. Affairs 
Media + PR 
press@boehringer-ingelheim.com

Linda Ruckel
Boehringer Ingelheim
Innovation Unit Communications
Linda.ruckel@boehringer-Ingelheim.com

 

Re-Vana:

Michele Gray 
Gray Communications, LLC
Michele@mgraycommunications.com
+1 917 449 9250


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.